Immunomedics Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///pills medical money
    Company & Industry Overviews

    Immunomedics Has Fallen More than 30% on January 18

    On January 18, Immunomedics (IMMU) is trading close to $12.27, which is ~32.17% lower than its previous closing price.

    By Margaret Patrick
  • uploads///Mirati
    Company & Industry Overviews

    Mirati Therapeutics Stock Has Delivered Solid Growth in 2018

    On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.

    By Daniel Collins
  • uploads///microscope _

    Here’s What’s Driving Investor Interest in Immunomedics

    Clinical stage biopharmaceutical company Immunomedics (IMMU) is currently focused on advancing several research programs.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Investors Not Impressed with Immunomedics’ IMMU-132 Study

    On June 6, 2016, biotech stocks continued their upward trend and appeared to be in a positive, consolidating mood. IBB rose 1.5% that day.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.